Company intelligence / Profile preview

VGI Health Technology

Lane Cove, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

VGI Health Technology has reached Phase 2 clinical trials in pancreatic cancer and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), with ethics approval granted for human trials. Its MELT3 nutraceuticals are ready for US commercial launch; clinical efficacy results have not yet been published in peer-reviewed format, but the company has reported successful trial initiation and human dosing for lead programs.[1][2][5][3][4][6][7]

Therapeutic areas: CardiovascularEndocrinologyRheumatologyGastroenterologyOtherOncology
Modalities: Small moleculeNutraceutical
Industry: Biotech

Drug pipeline

2 assets

IVB001

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Hebei Visual Medical Technology Co. Ltd

Beyond the preview

Go deeper on VGI Health Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGI Health Technology.

Explore the full profile